The Hims & Hers wellness platform announced Wednesday it will soon offer a generic version of the weight loss drug semaglutide in Canada as Novo Nordisk's patent on its branded version, known as ...

Recent health news includes trade restrictions on Brazilian chicken due to bird flu, potential U.S. tariffs on ...

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...

Novo Nordisk is a global diabetes and weight loss leader with strong long-term growth prospects. Read why NVO stock is a ...

Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

The pharmaceutical industry is criticizing the Trump administration’s plan for carrying out a critical round of Medicare drug ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

Wall Street hits record highs as payrolls surge. Explore healthcare stock movers, obesity drug breakthroughs, AbbVie deals, Centene struggles & ...

Novo Nordisk A/S (NYSE:NVO) ranks among the best set-it-and-forget-it stocks to buy. Novo Nordisk A/S (NYSE:NVO) announced on ...